Table 5 Subgroup analyses for the secondary endpoint secondary infection
Subgroup variables | Placebo (n = 366) | Prednisone (n = 361) | Logistic regression, OR (95%CI) | p for heterogeneity (interaction)b |
|---|---|---|---|---|
Median age | 0.328 | |||
 Age ≤ 73 years | 14/192 (7.3%) | 29/177 (16.4%) | 2.52 (1.28–4.95) |  |
 Age > 73 years | 21/174 (12.1%) | 33/184 (17.9%) | 1.60 (0.89–2.91) |  |
Initial median CRP | 0.114 | |||
 CRP ≤ 158 mg/L | 18/181 (9.9%) | 41/180 (22.8%) | 2.65 (1.46–4.83) |  |
 CRP > 158 mg/L | 17/182 (9.3%) | 21/179 (11.7%) | 1.28 (0.65–2.52) |  |
History of Chronic Obstructive Pulmonary Disease | 0.416 | |||
 no | 29/312 (9.3%) | 44/291 (15.1%) | 1.74 (1.06–2.86) |  |
 yes | 6/54 (11%) | 18/70 (26%) | 2.60 (0.94–7.20) |  |
Pneumonia severity indexa | 0.522 | |||
 PSI class I-III | 15/193 (7.8%) | 28/174 (16.1%) | 2.29 (1.18–4.44) |  |
 PSI class IV-V | 20/173 (11.6%) | 34/187 (18.2%) | 1.69 (0.93–3.08) |  |
Blood culture positivity | 0.720 | |||
 Blood culture negative | 29/321 (9.0%) | 52/324 (16.0%) | 1.92 (1.19–3.12) |  |
 Blood culture positive | 6/45 (13%) | 10/37 (27%) | 2.11 (0.66–6.72) |  |
Sex | 0.547 | |||
 Male | 19/231 (8.2%) | 36/219 (16.4%) | 2.20 (1.22–3.97) |  |
 Female | 16/135 (11.9%) | 26/142 (18.3%) | 1.66 (0.84–3.27) |  |
Microbiological etiology | ||||
 Bacterial proof | 0.391 | |||
   Yes | 12/87 (14%) | 17/81 (21%) | 1.58 (0.70–3.57) |  |
   No | 19/245 (7.8%) | 45/254 (17.7%) | 2.57 (1.46–4.55) |  |
 Viral proof | 0.209 | |||
   Yes | 2/38 (5%) | 9/38 (24%) | 5.71 (1.12–29.10) |  |
   No | 20/181 (11.0%) | 33/176 (18.8%) | 1.85 (1.01–3.37) |  |